Know Cancer

or
forgot password

Monitoring Targeted Lung Cancer Treatments With FDG-PET/CT


N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

Monitoring Targeted Lung Cancer Treatments With FDG-PET/CT


OBJECTIVES:

- Determine the prognostic significance of changes in glucose metabolism measured by
fludeoxyglucose F 18 positron emission tomography (FDG-PET)/CT scan in patients with
non-small cell lung cancer treated with targeted drugs comprising gefitinib, erlotinib
hydrochloride, or other ErbB inhibitors, cyclooxygenase-2 inhibitors, or estrogen
receptor blockers in combination with conventional chemotherapy.

OUTLINE: This is a prospective study.

Patients undergo fludeoxyglucose F 18 positron emission tomography (FDG-PET) scan and CT
scan at baseline and at 2 weeks and 12 weeks after receiving targeted anticancer treatment.
Metabolic changes detected by FDG-PET and size changes identified by CT scan are related to
patient outcome and tumor response to treatment.

PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.


Inclusion Criteria:



- Histologically or cytologically confirmed non-small cell lung cancer

- Any disease stage allowed

- Undergoing targeted treatment

Exclusion Criteria:

None

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Correlation of glucose metabolic response with progression-free survival, overall survival, and changes in tumor size as measured by fludeoxyglucose F 18 positron emission tomography/CT scan

Outcome Time Frame:

3 months

Safety Issue:

No

Principal Investigator

Johannes Czernin, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Jonsson Comprehensive Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

CDR0000423222

NCT ID:

NCT00450567

Start Date:

December 2004

Completion Date:

July 2012

Related Keywords:

  • Lung Cancer
  • recurrent non-small cell lung cancer
  • stage I non-small cell lung cancer
  • stage II non-small cell lung cancer
  • stage IIIA non-small cell lung cancer
  • stage IIIB non-small cell lung cancer
  • stage IV non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Jonsson Comprehensive Cancer Center at UCLALos Angeles, California  90095-1781